MindMed Announces Participation at Upcoming Investor Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced the participation of CEO Robert Barrow in several upcoming investor conferences. These include the Advances in Mental Health Virtual Conference on Sept. 22, 2021, CIBC's 20th Annual Eastern Institutional Conference on Sept. 23, and 2021 Cantor Virtual Global Healthcare Conference on Sept. 29. MindMed focuses on developing psychedelic-inspired therapies for addiction and mental illness, showcasing an innovative pipeline of treatments. Webcast replays will be available on MindMed's website for 30 days post-presentation.
- None.
- None.
NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announces that Robert Barrow, Chief Executive Officer of MindMed, will participate in the following investor conferences:
Advances in Mental Health Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest
Live Sessions Date: Wednesday, Sept. 22, 2021
Session Times: 12:00-1:00 p.m. ET and 1:00-2:00 p.m. ET
CIBC's 20th Annual Eastern Institutional Conference
Presentation Date: Thursday, Sept. 23, 2021
Presentation Time: 3:35-4:05 p.m. ET
2021 Cantor Virtual Global Healthcare Conference
Presentation Date: Wednesday, Sept. 29, 2021
Presentation Time: 2:00-2:30 p.m. ET
A replay of the webcasts will be available in the "Investors" section of MindMed's website for 30 days following each of the presentations.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Forward-Looking Statements
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding MindMed's participation in upcoming investor conferences. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings "Risk Factors" in the Company's filings with the securities regulatory authorities in all provinces and territories of Canada which are available under the Company's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.
Media Contact: mindmed@150bond.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-announces-participation-at-upcoming-investor-conferences-301381314.html
SOURCE Mind Medicine (MindMed) Inc.
FAQ
What conferences will MindMed CEO Robert Barrow participate in?
When is the Advances in Mental Health Virtual Conference?
What is the focus of MindMed's drug development pipeline?
Where can I find replays of MindMed's investor conference presentations?
What is the stock symbol for MindMed?
